Despite the existence of vaccines, the Hepatitis B virus (HBV) is still a serious global health concern. HBV targets liver cells. It has an unusual replication process involving an RNA pre-genome that the reverse transcriptase domain of the viral polymerase protein translates into viral DNA. The reverse transcription process is error prone and together with the high replication rates of the virus, allows the virus to exist as a heterogeneous population of mutants, known as a quasispecies, that can adapt and become resistant to antiviral therapy. This study presents an individual-based model of HBV inside an artificial liver, and associated blood serum, undergoing antiviral therapy. This model aims to provide insights into the evolution of the HBV quasispecies and the individual contribution of HBV mutations in the outcome of therapy. © Springer-Verlag Berlin Heidelberg 2009.
CITATION STYLE
Bernal, J., Dix, T., Allison, L., Bartholomeusz, A., & Yuen, L. (2009). Modelling hepatitis B virus antiviral therapy and drug resistant mutant strains. In Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) (Vol. 5865 LNAI, pp. 159–168). https://doi.org/10.1007/978-3-642-10427-5_16
Mendeley helps you to discover research relevant for your work.